{"id":"https://openalex.org/W7127053333","doi":"https://doi.org/10.1002/prp2.70217","title":"Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia","display_name":"Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia","publication_year":2026,"publication_date":"2026-02-01","ids":{"openalex":"https://openalex.org/W7127053333","doi":"https://doi.org/10.1002/prp2.70217","pmid":"https://pubmed.ncbi.nlm.nih.gov/41622624","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/12862099"},"language":"en","primary_location":{"id":"doi:10.1002/prp2.70217","doi":"https://doi.org/10.1002/prp2.70217","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.70217","pdf_url":null,"source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1002/prp2.70217","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032929583","display_name":"Shunsuke Kamigaso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shunsuke Kamigaso","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102762778","display_name":"Yoshihiro Konno","orcid":"https://orcid.org/0009-0005-7936-5890","observed_orcids":["https://orcid.org/0009-0005-7936-5890"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Yoshihiro Konno","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":"https://orcid.org/0009-0005-7936-5890","affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070380347","display_name":"Hirohiko Hikichi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hirohiko Hikichi","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055973215","display_name":"Daiji Kambe","orcid":"https://orcid.org/0000-0001-5134-3554","observed_orcids":["https://orcid.org/0000-0001-5134-3554"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Daiji Kambe","raw_affiliation_strings":["Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan"],"raw_orcid":"https://orcid.org/0000-0001-5134-3554","affiliations":[{"raw_affiliation_string":"Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067817332","display_name":"Yoko Mano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoko Mano","raw_affiliation_strings":["Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071350077","display_name":"Yuichi Tokumaru","orcid":"https://orcid.org/0009-0001-2425-7623","observed_orcids":["https://orcid.org/0009-0001-2425-7623"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuichi Tokumaru","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088283713","display_name":"Haruyuki Mori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Haruyuki Mori","raw_affiliation_strings":["Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5124725811","display_name":"Hironori Yamasaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hironori Yamasaki","raw_affiliation_strings":["Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5124693501","display_name":"Yukihiro Chino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukihiro Chino","raw_affiliation_strings":["Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Headquarters Taisho Pharmaceutical Co., Ltd.  Toshima Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079265287","display_name":"Kenji Hachiuma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Hachiuma","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058263346","display_name":"Akiko Mizuno\u2010Yasuhira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akiko Mizuno\u2010Yasuhira","raw_affiliation_strings":["Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center Taisho Pharmaceutical Co., Ltd.  Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5102762778"],"corresponding_institution_ids":["https://openalex.org/I144245601"],"apc_list":{"value":4160,"currency":"USD","value_usd":4160},"apc_paid":{"value":4160,"currency":"USD","value_usd":4160},"fwci":4.1658,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.87123927,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"14","issue":"1","first_page":"e70217","last_page":"e70217"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10316","display_name":"Sleep and related disorders","score":0.44290000200271606,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10316","display_name":"Sleep and related disorders","score":0.44290000200271606,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10985","display_name":"Sleep and Wakefulness Research","score":0.3407999873161316,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10342","display_name":"Circadian rhythm and melatonin","score":0.09009999781847,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dual-orexin-receptor-antagonists","display_name":"dual orexin receptor antagonists","score":0.8550000190734863},{"id":"https://openalex.org/keywords/orexin-1-receptor","display_name":"orexin-1 receptor","score":0.8690000176429749},{"id":"https://openalex.org/keywords/orexin-2-receptor","display_name":"orexin receptor 2","score":1.0},{"id":"https://openalex.org/keywords/insomnia-treatment","display_name":"insomnia treatment","score":0.8669999837875366},{"id":"https://openalex.org/keywords/sleep-promotion","display_name":"sleep promotion","score":0.7089999914169312},{"id":"https://openalex.org/keywords/plasma-pharmacokinetics","display_name":"plasma pharmacokinetics","score":0.7490000128746033},{"id":"https://openalex.org/keywords/sleep-maintenance","display_name":"sleep maintenance","score":0.8550000190734863}],"concepts":[{"id":"https://openalex.org/C160331591","wikidata":"https://www.wikidata.org/wiki/Q7075743","display_name":"Occupancy","level":2,"score":0.6590999960899353},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6590999960899353},{"id":"https://openalex.org/C2779680196","wikidata":"https://www.wikidata.org/wiki/Q410857","display_name":"Orexin","level":4,"score":0.6176999807357788},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5630999803543091},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5546000003814697},{"id":"https://openalex.org/C2779605129","wikidata":"https://www.wikidata.org/wiki/Q24785218","display_name":"Orexin receptor","level":5,"score":0.5042999982833862},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4943000078201294},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.4499000012874603},{"id":"https://openalex.org/C3020134792","wikidata":"https://www.wikidata.org/wiki/Q79749","display_name":"Human plasma","level":2,"score":0.40059998631477356},{"id":"https://openalex.org/C2775841894","wikidata":"https://www.wikidata.org/wiki/Q4683692","display_name":"Sleep (system call)","level":2,"score":0.39899998903274536},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3970000147819519},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3880999982357025},{"id":"https://openalex.org/C2781210498","wikidata":"https://www.wikidata.org/wiki/Q1869874","display_name":"Insomnia","level":2,"score":0.3853999972343445},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3758000135421753},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35269999504089355},{"id":"https://openalex.org/C2776119998","wikidata":"https://www.wikidata.org/wiki/Q1070023","display_name":"Orexin-A","level":5,"score":0.33320000767707825},{"id":"https://openalex.org/C2779494582","wikidata":"https://www.wikidata.org/wiki/Q189561","display_name":"Narcolepsy","level":3,"score":0.3127000033855438},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.31029999256134033},{"id":"https://openalex.org/C2778205975","wikidata":"https://www.wikidata.org/wiki/Q1754874","display_name":"Polysomnography","level":3,"score":0.2567000091075897}],"mesh":[{"descriptor_ui":"D000068796","descriptor_name":"Orexin Receptor Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068796","descriptor_name":"Orexin Receptor Antagonists","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000068796","descriptor_name":"Orexin Receptor Antagonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000068796","descriptor_name":"Orexin Receptor Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007319","descriptor_name":"Sleep Initiation and Maintenance Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064446","descriptor_name":"Orexin Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1002/prp2.70217","doi":"https://doi.org/10.1002/prp2.70217","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.70217","pdf_url":null,"source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12862099","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12862099/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12862099/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacol Res Perspect","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:11669702","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12862099","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:41622624","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41622624","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology research & perspectives","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:5aaa0cb14c6a4b3b9c1c15e784b0521c","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/5aaa0cb14c6a4b3b9c1c15e784b0521c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives, Vol 14, Iss 1, Pp n/a-n/a (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/prp2.70217","doi":"https://doi.org/10.1002/prp2.70217","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.70217","pdf_url":null,"source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320323880","display_name":"Taisho Toyama Pharmaceutical Company","ror":"https://ror.org/033nw2736"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7127053333.pdf","grobid_xml":"https://content.openalex.org/works/W7127053333.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W35150762","https://openalex.org/W1519232679","https://openalex.org/W1581771528","https://openalex.org/W1888364249","https://openalex.org/W1902706583","https://openalex.org/W1983298714","https://openalex.org/W2003879268","https://openalex.org/W2009111005","https://openalex.org/W2024674930","https://openalex.org/W2027740042","https://openalex.org/W2051361436","https://openalex.org/W2098040987","https://openalex.org/W2101362443","https://openalex.org/W2111180320","https://openalex.org/W2111723991","https://openalex.org/W2129357751","https://openalex.org/W2152211310","https://openalex.org/W2210115974","https://openalex.org/W2411728512","https://openalex.org/W2417418657","https://openalex.org/W2621833103","https://openalex.org/W2733785551","https://openalex.org/W2753901523","https://openalex.org/W2990672304","https://openalex.org/W3015290109","https://openalex.org/W4210790547","https://openalex.org/W4220920422","https://openalex.org/W4385751478","https://openalex.org/W4392882813","https://openalex.org/W4411081245","https://openalex.org/W4414554668"],"related_works":["https://openalex.org/W4411081245","https://openalex.org/W2051361436","https://openalex.org/W3030081581","https://openalex.org/W4385751478","https://openalex.org/W1975898841","https://openalex.org/W4416554409","https://openalex.org/W3084068073","https://openalex.org/W4392882813","https://openalex.org/W3158309558","https://openalex.org/W2619950834"],"abstract_inverted_index":{"ABSTRACT":[0],"Vornorexant":[1,208],"is":[2,84],"a":[3,16,42,211],"novel":[4],"dual":[5],"orexin":[6,24],"receptor":[7,25,59,109,146,166,201],"antagonist":[8],"(DORA)":[9],"for":[10,47,189,215],"the":[11,22,31,34,65,78,131,142,154,174,198,205],"treatment":[12],"of":[13,21,33,37,72,77,97,100,115,141,153,197],"insomnia":[14],"with":[15,169,223],"short":[17,170],"elimination":[18],"half\u2010life.":[19],"Estimation":[20],"human":[23,66,79,106,143,160],"occupancy":[26,44,60,76,110,132,167,202],"can":[27],"provide":[28],"insight":[29],"into":[30],"duration":[32],"sleep\u2010promoting":[35,136,184],"effect":[36],"DORAs.":[38],"Herein,":[39],"we":[40],"developed":[41],"pharmacokinetic\u2010receptor":[43],"(PK/RO)":[45],"model":[46],"OX":[48,51,80,107,144,155,161,164,199],"1":[49,145,162],"and":[50,56,102,117,126,163,186,194,219],"2":[52,81,108,156,165,200],"receptors":[53],"in":[54,61,87,138,228],"rats":[55],"estimated":[57,75,121,159],"their":[58],"humans":[62],"based":[63],"on":[64,173],"plasma":[67,175],"concentrations":[68],"after":[69,95],"oral":[70],"administration":[71],"vornorexant.":[73],"The":[74,105,158],"receptor,":[82],"which":[83],"primarily":[85],"involved":[86],"sleep":[88,188,217,221],"induction,":[89],"exceeded":[90],"70%":[91],"at":[92,111,190],"30":[93],"min":[94],"dosing":[96],"therapeutic":[98],"doses":[99],"5":[101,116],"10":[103,118],"mg.":[104],"6":[112,192],"h":[113],"post\u2010dose":[114],"mg":[119],"was":[120,149],"to":[122,130,134],"be":[123],"approximately":[124],"50%":[125],"60%,":[127],"respectively,":[128],"comparable":[129],"necessary":[133],"exert":[135],"effects":[137,185,227],"rats.":[139],"Occupancy":[140],"by":[147],"vornorexant":[148,181],"higher":[150],"than":[151],"that":[152,180],"receptor.":[157],"decreased":[168],"half\u2010lives":[171],"depending":[172],"concentration.":[176],"These":[177],"results":[178],"suggest":[179],"exerts":[182],"rapid":[183,216],"maintains":[187],"least":[191],"h,":[193],"these":[195],"estimations":[196],"could":[203],"support":[204],"clinical":[206],"results.":[207],"may":[209],"have":[210],"favorable":[212],"PK/RO":[213],"profile":[214],"onset":[218],"sufficient":[220],"maintenance":[222],"minimal":[224],"next\u2010day":[225],"residual":[226],"humans.":[229]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-02-03T00:00:00"}